Publications

Gatifloxacin Phase IV surveillance trial (TeqCES Study) utilizing 5,000 primary care physician practices: Report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. by Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 77-84

Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. by Jones RN, Andes DR, Mandell LA, Gothelf S, Ehrhardt AF and Nicholson SC published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 93-100

Implications of TeqCES: Efficacy and safety of gatifloxacin in community-acquired pneumonia. by Mandell LA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 127-128

Haemophilus influenzae in respiratory tract infections in community-based clinical practice: Therapy with gatifloxacin. by Nicholson SC, Webb CD, Andriole VT, Jones RN and Wilson WR published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 101-107

Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: Report of the Zyvox®; Antimicrobial Potency Study in Latin America (LA-ZAPS). by LA-ZAPS Study Group, Ballow CH, Biedenbach DJ, Rossi F and Jones RN published in Braz. J. Infect. Dis. 2002; 6 (3): 100-109

Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (4): 323-326

In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY Antimicrobial Surveillance Program (1998-1999). by Bell JM, Turnidge JD, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (4): 315-318

Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (2000). by Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA and The SENTRY Participants Group published in Diagn. Microbiol. Infect. Dis. 2002; 43 (4): 303-309

Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: Report from the Zyvox® Antimicrobial Potency Study (ZAPS-Europe). by Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ and Jones RN published in Clin. Microbiol. Infect. 2002; 8 (12): 791-800

Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: Summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). by Jones RN, Kirby JT, Beach ML, Biedenbach DJ and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2002; 43 (3): 239-243

In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. by Anderegg TR, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 2002; 46 (8): 2662-2664

In vitro evaluation of AZD2563, a new oxazolidinone, tested against beta-haemolytic and viridans group streptococci. by Anderegg TR, Biedenbach DJ and Jones RN published in J. Antimicrob. Chemother. 2002; 49 (6): 1019-1021

AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains. by Jones RN, Anderegg TR and Deshpande LM published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 87-90

A multicentre evaluation of linezolid antimicrobial activity in North America. by Ballow CH, Jones RN, Biedenbach DJ and North American ZAPS Research Group published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 75-83

Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): Emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. by Johnson DM, Biedenbach D and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 49-60

Quality control guidelines for tiamulin (Denagard^TM) susceptibility testing. by Walter D, Pfaller MA and Jones RN published in Proceedings of the 17th IPVS Congress, Ames, IA June 2-5, 2002; Vol 2: 256

Interpretive criteria for tiamulin (Denagard^TM) susceptibility testing. by Walter D, Jones RN, Pfaller MA published in Proceedings of the 17th IPVS Congress, Ames, IA 2002; Vol 2: 80

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. by Pfaller MA, Messer SA, Hollis RJ, Jones RN and Diekema DJ published in Antimicrob. Agents Chemother. 2002; 46 (6): 1723-1727

Antimicrobial susceptibilities of H. influenzae and M. catarrhalis causing lower respiratory tract infections: SENTRY Antimicrobial Surveillance Program, Europe 2000. Abstr. P1109. by Loza E, Canton R, Morosini MI, Jones RN, Baquero F and The SENTRY Participants Group published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):250-251

Validation of commercial dry-form panels (Sensititre) for the susceptibility testing of AZD2563, a new long-Acting Oxazolidinone. Abstr. #P1045. by Jones RN, Anderegg T, Biedenbach DJ and Rhomberg P published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1): 233

Intermethod agreement and preliminary quality control (QC) guidelines for susceptibility testing AZD2563 by disk diffusion and MIC methods. by Anderegg T and Jones RN published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1): 232-233

Epidemiology of antibiotic resistance of bacterial pathogens from intensive care units: The SENTRY Surveillance Program in Europe 2000. by Rodriguez-Villalobos H, Jones RN, Struelens MJ published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):196-197

In vitro activity of meropenem, imipenem, piperacillin/tazobactam, ciprofloxacin, amikacin, and cefepime against P. aeruginosa and A. baumannii isolated from Brazilian intensive care units: MYSTIC Study Group (Brazil 2001). by Mendes C, Kiffer C, Oplustil C, Sinto S, Turner P, Jones RN and Hsiung A published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1): 165

Tracking Streptococcus pneumoniae isolates with decreased antimicrobial susceptibility by MIC distribution analysis: SENTRY, Europe 1997-2000. Abstr. #P456 by Canton R, Loza E, Morosini MI, Voerhoef J and Jones RN published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):75

Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: Report from the SENTRY Antimicrobial Surveillance Program (1998-1999) including an in vitro evaluation of BMS284756. by Bell J, Turnidge J, Jones RN and SENTRY Regional Participants Group published in Int. J. Antimicrob. Agents 2002; 19 (2): 125-132

Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli. by Howard W, Biedenbach DJ, Jones RN published in Clin. Microbiol. Infect. 2002; 8: 340-344

Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons. by Pfaller MA, Jones RN, Biedenbach DJ, Beach ML published in J. Chemother. 2002; 14 (1): 13-18

Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. by Nicholson SC, Naughton BJ, Webb CD. published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 117-125

Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. by Nicholson SC, High KP, Gothelf S and Webb CD published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 109-116

Oral gatifloxacin in outpatient community-acquired pneumonia: Results from TeqCES, a community-based, open-label, multicenter study. by Gotfried M, Quinn T, Gothelf S, Wikler MA, Webb CD and Nicholson SC. published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 85-91

Safety and efficacy of gatifloxacin in community-acquired pneumonia: Rationale for the Tequin Clinical Experience Study (TeqCES). by Mandell LA published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 65-67

Emerging antimicrobial resistances among Proteus mirabilis in Europe: Report from the MYSTIC Program (1997-2001). by Mutnick AH, Turner PJ and Jones RN published in J. Chemother. 2002; 14 (3): 253-258

Antimicrobial susceptibility patterns of Beta-hemolytic and viridans group streptococci: Report from the SENTRY Antimicrobial Surveillance Program (1997-2000). by Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR and Mutnick AH published in Diagn. Microbiol. Infect. Dis. 2002; 43 (2): 157-162

Spectrum and potency evaluation of a new oxazolidinone, linezolid: Report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. by Mutnick AH, Biedenbach DJ, Turnidge JD and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 65-73

First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan. by Yu WL, Winokur PL, Von Stein DL, Pfaller MA, Wang JH and Jones RN published in Antimicrob Agents Chemother 2002; 46 (4): 1098-1100

Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan. by Yu WL, Pfaller MA, Winokur PL and Jones RN published in Emerg. Infect. Dis. 2002; 8 (5): 522-524

In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. by Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 145-147

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. by Pfaller MA, Diekema DJ, Jones RN, Messer SA and Hollis RJ published in J. Clin. Microbiol. 2002; 40 (3): 852-856

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. by Pfaller MA, Messer SA, Hollis RJ and Jones RN published in Antimicrob. Agents Chemother. 2002; 46 (4): 1032-1037

Antimicrobial susceptibility of inducible AmpC β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. by Pfaller MA and Jones RN published in Int. J. Antimicrob. Agents 2002; 19 (5): 383-388

Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: Initial development of in vitro susceptibility test methods. by Jones RN, Pfaller MA, Rhomberg PR and Walter DH. published in J. Clin. Microbiol. 2002; 40 (2): 461-465

In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species. by Jones RN, Biedenbach DJ and Anderegg TR published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 119-122

Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Della-Latta P, Lee LV and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 137-139

Ciprofloxacin as broad-spectrum empiric therapy–are fluoroquinolones still viable monotherapeutic agents compared with β-lactams: Data from the MYSTIC Program (US) by Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2002; 42 (3): 213-215

BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Programme (2000). by Gordon KA, Pfaller MA and Jones RN. published in J. Antimicrob. Chemother. 2002; 49 (5): 851-855

Antimicrobial resistance in Gram-negative isolates from European intensive care units: Data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme. by Garcia-Rodriguez JA and Jones RN published in J. Chemother. 2002; 14 (1): 25-32

Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): Correlations of results from disk diffusion, Etest and reference dilution methods. by Deshpande LM, Fix AM, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (4): 283-290

Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil. by Cereda RF, Gales AC, Silbert S, Jones RN and Sader HS published in Infect. Control. Hosp. Epidemiol. 2002; 23 (1): 19-22

Pharmacodynamics in the evaluation of drug regimens. by Bhavnani SM, Ambrose PG and Jones RN published in Ann. Pharmacother. 2002; 36 (3): 530-532

Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: Regional results from SENTRY Antimicrobial Surveillance Program (1998-99). by Bell JM, Turnidge JD, Gales AC, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (3): 193-198